Compare Stocks: STTK, CDNA, NKTR, and VERA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDNA CareDx	$50.26 +0.5%	$42.84	$13.23 ▼ $53.67	$2.60B	2.43	1.10 million shs	662,907 shs
NKTR Nektar Therapeutics	$69.76 -1.3%	$72.24	$33.40 ▼ $109.00	$2.38B	1.14	575,892 shs	784,031 shs
STTK Shattuck Labs	$6.20 +0.8%	$7.11	$1.70 ▼ $8.33	$622.25M	1.09	725,819 shs	846,932 shs
VERA Vera Therapeutics	$35.05 +4.3%	$35.11	$22.72 ▼ $56.05	$2.53B	0.96	1.95 million shs	3.80 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDNA CareDx	0.00%	-1.22%	+6.08%	+118.81%	+277.04%
NKTR Nektar Therapeutics	0.00%	-5.97%	-8.11%	+17.48%	+44.79%
STTK Shattuck Labs	0.00%	-8.69%	-15.30%	+25.51%	+254.29%
VERA Vera Therapeutics	0.00%	-2.34%	+21.32%	+2.31%	+43.88%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDNA CareDx	$50.26 +0.5%	$42.84	$13.23 ▼ $53.67	$2.60B	2.43	1.10 million shs	662,907 shs
NKTR Nektar Therapeutics	$69.76 -1.3%	$72.24	$33.40 ▼ $109.00	$2.38B	1.14	575,892 shs	784,031 shs
STTK Shattuck Labs	$6.20 +0.8%	$7.11	$1.70 ▼ $8.33	$622.25M	1.09	725,819 shs	846,932 shs
VERA Vera Therapeutics	$35.05 +4.3%	$35.11	$22.72 ▼ $56.05	$2.53B	0.96	1.95 million shs	3.80 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDNA CareDx	0.00%	-1.22%	+6.08%	+118.81%	+277.04%
NKTR Nektar Therapeutics	0.00%	-5.97%	-8.11%	+17.48%	+44.79%
STTK Shattuck Labs	0.00%	-8.69%	-15.30%	+25.51%	+254.29%
VERA Vera Therapeutics	0.00%	-2.34%	+21.32%	+2.31%	+43.88%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDNA CareDx	2.63	Moderate Buy	$51.20	1.87% Upside
NKTR Nektar Therapeutics	2.77	Moderate Buy	$141.50	102.84% Upside
STTK Shattuck Labs	3.00	Buy	$12.78	106.09% Upside
VERA Vera Therapeutics	2.86	Moderate Buy	$80.15	128.68% Upside

Current Analyst Ratings Breakdown

Latest STTK, CDNA, NKTR, and VERA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$178.00
9/8/2026	VERA Vera Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$76.00 ➝ $83.00
9/2/2026	CDNA CareDx	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$65.00
9/2/2026	CDNA CareDx	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$65.00
8/28/2026	NKTR Nektar Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/24/2026	STTK Shattuck Labs	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Strong-Buy	$18.00
8/24/2026	NKTR Nektar Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/24/2026	STTK Shattuck Labs	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Strong-Buy	$18.00
8/24/2026	STTK Shattuck Labs	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	NKTR Nektar Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$65.00
8/17/2026	VERA Vera Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$34.00

(Data available from 9/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDNA CareDx	$379.80M	6.85	$0.01 per share	7,716.40	$5.89 per share	8.53
NKTR Nektar Therapeutics	$55.23M	43.12	N/A	N/A	$4.41 per share	15.82
STTK Shattuck Labs	$1M	622.23	N/A	N/A	$1.30 per share	4.77
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	$8.48 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDNA CareDx	-$21.35M	$2.07	24.28	79.78	N/A	24.23%	2.87%	2.17%	11/3/2026 (Estimated)
NKTR Nektar Therapeutics	-$164.08M	-$6.70	N/A	N/A	N/A	-287.84%	-37.87%	-25.67%	11/5/2026 (Estimated)
STTK Shattuck Labs	-$48.81M	-$0.51	N/A	N/A	N/A	N/A	-43.57%	-40.90%	11/10/2026 (Estimated)
VERA Vera Therapeutics	-$299.61M	-$5.86	N/A	N/A	N/A	N/A	-84.13%	-66.79%	11/4/2026 (Estimated)

Latest STTK, CDNA, NKTR, and VERA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	NKTR Nektar Therapeutics	-$1.97	-$1.23	+$0.74	-$1.23	$10.43 million	$10.13 million
8/11/2026	Q2 2026	STTK Shattuck Labs	-$0.1241	-$0.12	+$0.0041	-$0.12	N/A	N/A
8/10/2026	Q2 2026	VERA Vera Therapeutics	-$1.58	-$1.52	+$0.06	-$1.52	$1.28 million	N/A
7/30/2026	Q2 2026	CDNA CareDx	$0.2321	$0.37	+$0.1379	$2.07	$114.05 million	$131.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDNA CareDx	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A
STTK Shattuck Labs	N/A	N/A	N/A	N/A	N/A
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDNA CareDx	N/A	4.58	4.51
NKTR Nektar Therapeutics	N/A	10.42	10.42
STTK Shattuck Labs	N/A	27.59	27.59
VERA Vera Therapeutics	0.18	10.92	10.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDNA CareDx	N/A
NKTR Nektar Therapeutics	75.88%
STTK Shattuck Labs	58.74%
VERA Vera Therapeutics	99.21%

Insider Ownership

Company	Insider Ownership
CDNA CareDx	2.40%
NKTR Nektar Therapeutics	2.50%
STTK Shattuck Labs	8.79%
VERA Vera Therapeutics	15.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDNA CareDx	765	51.73 million	50.49 million	Optionable
NKTR Nektar Therapeutics	63	34.14 million	33.29 million	Optionable
STTK Shattuck Labs	100	100.36 million	91.54 million	Optionable
VERA Vera Therapeutics	361	72.06 million	60.61 million	Optionable

STTK, CDNA, NKTR, and VERA Headlines

Recent News About These Companies

Vera Therapeutics, Inc. $VERA Shares Purchased by Engineers Gate Manager LP

September 13 at 4:08 AM | marketbeat.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Recommendation of "Moderate Buy" from Brokerages

September 13 at 2:28 AM | americanbankingnews.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of "Moderate Buy" by Analysts

September 13 at 2:28 AM | marketbeat.com

Squarepoint Ops LLC Acquires 89,253 Shares of Vera Therapeutics, Inc. $VERA

September 12 at 4:48 AM | marketbeat.com

Wellington Management Group LLP Has $987,000 Stock Position in Vera Therapeutics, Inc. $VERA

September 12 at 4:23 AM | marketbeat.com

JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Vera Therapeutics (NASDAQ:VERA) Stock

September 10 at 1:24 AM | americanbankingnews.com

JPMorgan Chase & Co. Issues Positive Forecast for Vera Therapeutics (NASDAQ:VERA) Stock Price

September 8, 2026 | marketbeat.com

Readystate Asset Management LP Takes Position in Vera Therapeutics, Inc. $VERA

September 7, 2026 | marketbeat.com

Insider Selling: Vera Therapeutics (NASDAQ:VERA) CEO Sells $649,720.00 in Stock

September 7, 2026 | americanbankingnews.com

Vera Therapeutics (NASDAQ:VERA) CEO Sells $649,720.00 in Stock

September 4, 2026 | marketbeat.com

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 4, 2026 | globenewswire.com

Braidwell LP Purchases 40,900 Shares of Vera Therapeutics, Inc. $VERA

September 3, 2026 | marketbeat.com

Vera Therapeutics to Participate at Upcoming Investor Conferences

September 1, 2026 | globenewswire.com

AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual ...

August 31, 2026 | joplinglobe.comJ

Vera Therapeutics (NASDAQ:VERA) Trading Down 5.2% - What's Next?

August 27, 2026 | marketbeat.com

Vera Therapeutics, Inc. $VERA Stock Position Raised by Odyssean LLC

August 26, 2026 | marketbeat.com

Vera Therapeutics Sees Unusually Large Options Volume (NASDAQ:VERA)

August 25, 2026 | marketbeat.com

Vera Therapeutics, Inc. (VERA) Stock Price, News, Quote & History - Yahoo Finance

August 25, 2026 | finance.yahoo.com

Vera Therapeutics (NASDAQ:VERA) Stock Price Up 6.2% - Here's What Happened

August 24, 2026 | marketbeat.com

Vera Therapeutics (NASDAQ:VERA): What Could Drive the Next Move?

August 19, 2026 | kalkinemedia.comK

J.P. Morgan Sticks to Their Buy Rating for Vera Therapeutics (VERA)

August 19, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

STTK, CDNA, NKTR, and VERA Company Descriptions

CareDx NASDAQ:CDNA

$50.26 +0.24 (+0.48%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$50.32 +0.06 (+0.12%)

As of 09/11/2026 07:57 PM Eastern

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Nektar Therapeutics NASDAQ:NKTR

$69.76 -0.89 (-1.26%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$69.97 +0.21 (+0.30%)

As of 09/11/2026 07:34 PM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Shattuck Labs NASDAQ:STTK

$6.20 +0.05 (+0.81%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$6.20 0.00 (0.00%)

As of 09/11/2026 07:30 PM Eastern

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

Vera Therapeutics NASDAQ:VERA

$35.05 +1.45 (+4.32%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$34.80 -0.25 (-0.70%)

As of 09/11/2026 07:47 PM Eastern

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest STTK, CDNA, NKTR, and VERA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest STTK, CDNA, NKTR, and VERA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

STTK, CDNA, NKTR, and VERA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

STTK, CDNA, NKTR, and VERA Company Descriptions

CareDx NASDAQ:CDNA

Nektar Therapeutics NASDAQ:NKTR

Shattuck Labs NASDAQ:STTK

Vera Therapeutics NASDAQ:VERA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest STTK, CDNA, NKTR, and VERA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest STTK, CDNA, NKTR, and VERA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

STTK, CDNA, NKTR, and VERA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

STTK, CDNA, NKTR, and VERA Company Descriptions

CareDx NASDAQ:CDNA

Nektar Therapeutics NASDAQ:NKTR

Shattuck Labs NASDAQ:STTK

Vera Therapeutics NASDAQ:VERA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools